Biotech | April 08, 2022
CDSCO approves Phase II/III trial of Akston Bio’s Covid vaccine candidate in India
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
BioFluidica LiquidScan harnesses the power of microfluidics
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
He has done his Masters in Pharmacy (M. Pharm) and Post Graduate Diploma in Personnel Management & Industrial Relations
Subscribe To Our Newsletter & Stay Updated
